首页> 外国专利> Process for the treatment of glomerulonephritis in a patient in need of this treatment article of manufacture hybridoma antibody 5g.1; 1 isolated nucleic acid protein isolated polypeptide vector recombinant host cell nucleic acid vector process to produce an isolated isolated anti-c5 antibody c5 polypeptide process to produce an isolated anti-c5 antibody protein isolated nucleic acid molecule process to produce an anti-c5 antibody anti-c5 antibody 5g46k fragment 5g27k peptide 5g325aa isolated peptide 5g200aa isolated oligopeptide isolated process to induce an animal to produce an anti- c5 process for identifying an anti-c5 antibody and process for treating a patient in need of complete inhibition

Process for the treatment of glomerulonephritis in a patient in need of this treatment article of manufacture hybridoma antibody 5g.1; 1 isolated nucleic acid protein isolated polypeptide vector recombinant host cell nucleic acid vector process to produce an isolated isolated anti-c5 antibody c5 polypeptide process to produce an isolated anti-c5 antibody protein isolated nucleic acid molecule process to produce an anti-c5 antibody anti-c5 antibody 5g46k fragment 5g27k peptide 5g325aa isolated peptide 5g200aa isolated oligopeptide isolated process to induce an animal to produce an anti- c5 process for identifying an anti-c5 antibody and process for treating a patient in need of complete inhibition

机译:在需要该治疗制品的患者中治疗肾小球肾炎的方法制造杂交瘤抗体5g.1; 1分离的核酸蛋白分离的多肽载体重组宿主细胞核酸载体的过程产生分离的分离的抗c5抗体c5多肽的过程产生分离的抗c5抗体分离的蛋白分子分子过程产生抗c5抗体c5抗体5g46k片段5g27k肽5g325aa分离的肽5g200aa分离的寡肽分离的方法,以诱导动物产生用于鉴定抗c5抗体的抗c5方法以及用于治疗需要完全抑制的患者的方法

摘要

The present invention relates to an antibody characterised in that it comprises at least one antibody-antigen binding site, exhibits specific binding to human complement component C5, said specific binding being targeted to the alpha chain of human complement component C5, inhibits complement activation in a human body fluid and does not specifically bind to the human complement activation product free C5a, wherein the antibody binds specifically with (i) a fragment comprising amino acid residues 660-1019 of SEQ ID NO:2; (ii) a peptide comprising amino acid residues 725-1049 of SEQ ID NO:2; (iii) a peptide comprising amino acid residues 850-1049 of SEQ ID NO:2; or (iv) a peptide comprising the amino acid sequence of SEQ ID NO:1.
机译:本发明涉及一种抗体,其特征在于它包含至少一个抗体-抗原结合位点,表现出与人补体组分C5的特异性结合,所述特异性结合靶向人补体组分C5的α链,抑制人补体组分C5的补体活化。抗体,其不与不含人补体激活产物的C5a特异性结合,其中所述抗体与(i)包含SEQ ID NO:2的氨基酸残基660-1019的片段特异性结合; (ii)包含SEQ ID NO:2的氨基酸残基725-1049的肽; (iii)包含SEQ ID NO:2的氨基酸残基850-1049的肽; (iv)包含氨基酸序列SEQ ID NO:1的肽。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号